Anika Therapeutics (ANIK) Current Leases (2019 - 2026)

Anika Therapeutics (ANIK) has 8 years of Current Leases data on file, last reported at $1.9 million in Q1 2026.

• Current Leases for Q1 2026 came in at $1.9 million, up 3.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 3.63% YoY), and the FY2025 annual result was $2.1 million, up 6.99% from the prior year.
• Current Leases declined to $1.9 million in Q1 2026 per ANIK's latest filing, from $2.1 million in the prior quarter.
• Over five years, Current Leases peaked at $2.3 million in Q3 2024 and troughed at $122000.0 in Q1 2022.
• A 5-year average of $1.9 million and a median of $1.9 million in 2026 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2025: Current Leases surged 1625.41% in 2023, then fell 24.74% in 2025.
• A 5-year view of Current Leases shows it stood at $2.1 million in 2022, then retreated by 11.87% to $1.8 million in 2023, then rose by 4.98% to $1.9 million in 2024, then gained by 6.99% to $2.1 million in 2025, then fell by 5.36% to $1.9 million in 2026.
• Business Quant data shows ANIK's Current Leases at $1.9 million in Q1 2026, $2.1 million in Q4 2025, and $1.7 million in Q3 2025.